Table 2.
Results of the diagnostic tests performed between the CRC patients and the controls.
| Stages | Markers | Cutoff | AUC (95%CI) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|---|---|
| All CRC | CXCL7 | 1.30 | 0.862 (0.831–0.890) | 85.00 | 80.71 | 81.51 | 84.33 |
| CEA | 2.46 | 0.834 (0.800–0.863) | 71.07 | 82.14 | 79.92 | 73.95 | |
| CA125 | 6.45 | 0.749 (0.711–0.785) | 85.71 | 61.79 | 69.16 | 81.22 | |
| CA19-9 | 15.14 | 0.697 (0.657–0.735) | 46.43 | 92.50 | 86.09 | 63.33 | |
| Combination | 2.50 | 0.933 (0.909–0.952) | 87.14 | 87.50 | 87.50 | 87.50 | |
| Stage I–II | CXCL7 | 1.28 | 0.823 (0.783–0.858) | 80.00 | 78.93 | 65.91 | 88.35 |
| CEA | 2.46 | 0.818 (0.778–0.854) | 68.97 | 82.14 | 66.67 | 83.64 | |
| CA125 | 6.45 | 0.746 (0.702–0.787) | 87.59 | 61.79 | 54.27 | 90.58 | |
| CA19-9 | 9.10 | 0.632 (0.585–0.678) | 52.41 | 77.14 | 54.29 | 75.79 | |
| Combination | 2.66 | 0.904 (0.872–0.930) | 82.76 | 87.14 | 76.43 | 90.67 | |
| Male subgroup | CXCL7 | 1.30 | 0.909 (0.874–0.937) | 87.95 | 85.39 | 84.88 | 88.37 |
| CEA | 2.51 | 0.817 (0.772–0.857) | 70.48 | 83.15 | 79.59 | 75.31 | |
| CA125 | 6.45 | 0.766 (0.718–0.810) | 84.34 | 67.98 | 71.07 | 82.31 | |
| CA19-9 | 9.76 | 0.692 (0.640–0.740) | 59.04 | 79.78 | 73.13 | 67.62 | |
| Combination | 2.13 | 0.947 (0.917–0.968) | 86.14 | 94.96 | 94.08 | 88.02 | |
| Female subgroup | CXCL7 | 1.43 | 0.783 (0.722–0.836) | 78.07 | 78.43 | 80.18 | 76.19 |
| CEA | 1.98 | 0.860 (0.806–0.903) | 84.21 | 75.49 | 79.34 | 81.05 | |
| CA125 | 6.30 | 0.724 (0.660–0.783) | 89.47 | 50.00 | 66.67 | 80.95 | |
| CA19-9 | 16.77 | 0.706 (0.640–0.766) | 47.37 | 96.08 | 93.10 | 62.03 | |
| Combination | 4.63 | 0.919 (0.874–0.951) | 72.81 | 98.04 | 96.51 | 76.15 |